Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study

다국어 초록 (Multilingual Abstract)

.

참고문헌 (Reference)

1 Shah SH, "Uterine sarcomas: then and now" 199 : 213-223, 2012

2 Cantrell LA, "Uterine carcinosarcoma: a review of the literature" 137 : 581-588, 2015

3 Pacaut C, "Uterine and ovary carcinosarcomas: outcome, prognosis factors, and adjuvant therapy" 38 : 272-277, 2015

4 Menczer J, "Review of recommended treatment of uterine carcinosarcoma" 16 : 53-, 2015

5 Harano K, "Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group" 21 : 168-176, 2016

6 Homesley HD, "Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study" 25 : 526-531, 2007

7 Powell MA, "Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study" 28 : 2727-2731, 2010

8 Kim JW, "Pazopanib maintenance therapy in East Asian women with advanced epithelial ovarian cancer: results from AGO-OVAR16 and an East Asian Study" 2015

9 van der Graaf WT, "Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial" 379 : 1879-1886, 2012

10 National Comprehensive Cancer Network (US), "NCCN clinical practice guidelines in oncology (NCCN Guidelines®): uterine neoplasms version 2" National Comprehensive Cancer Network

11 Wada H, "Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors" 57 : 5379-5385, 1997

12 du Bois A, "Incorporation of pazopanib in maintenance therapy of ovarian cancer" 32 : 3374-3382, 2014

13 Berton-Rigaud D, "Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma" 24 : S55-60, 2014

14 Galaal K, "Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma" 143 : 88-92, 2009

15 Huh WK, "Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus" 117 : 248-254, 2010

16 Gokce ZK, "Clinical outcomes of uterine carcinosarcoma: results of 94 patients" 25 : 279-287, 2015

17 Cantrell LA, "Carcinosarcoma of the ovary a review" 64 : 673-680, 2009

18 Hoskins PJ, "Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed mullerian tumors. The British Columbia Cancer Agency experience" 108 : 58-62, 2008

19 Campos SM, "A phase II evaluation of pazopanib in the treatment of recurrent or persistent carcinosarcoma of the uterus: a gynecologic oncology group study" 133 : 537-541, 2014